Cresset Asset Management LLC Has $6.05 Million Stock Holdings in Danaher Corporation $DHR

Cresset Asset Management LLC trimmed its stake in shares of Danaher Corporation (NYSE:DHR) by 27.2% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 30,592 shares of the conglomerate’s stock after selling 11,422 shares during the quarter. Cresset Asset Management LLC’s holdings in Danaher were worth $6,053,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of the stock. Vanguard Group Inc. grew its position in Danaher by 1.3% in the second quarter. Vanguard Group Inc. now owns 60,769,587 shares of the conglomerate’s stock valued at $12,004,424,000 after acquiring an additional 788,499 shares during the period. Price T Rowe Associates Inc. MD boosted its stake in shares of Danaher by 3.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 19,592,211 shares of the conglomerate’s stock valued at $4,016,404,000 after purchasing an additional 612,154 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Danaher by 0.6% in the 2nd quarter. Geode Capital Management LLC now owns 13,726,194 shares of the conglomerate’s stock worth $2,697,800,000 after purchasing an additional 81,670 shares during the last quarter. Norges Bank acquired a new stake in shares of Danaher during the 2nd quarter worth about $1,979,503,000. Finally, Generation Investment Management LLP lifted its holdings in Danaher by 56.2% during the 2nd quarter. Generation Investment Management LLP now owns 4,965,646 shares of the conglomerate’s stock valued at $980,914,000 after purchasing an additional 1,787,522 shares during the last quarter. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher Stock Down 0.4%

Shares of DHR opened at $226.20 on Friday. The business’s fifty day moving average price is $216.22 and its two-hundred day moving average price is $204.36. The firm has a market capitalization of $159.78 billion, a price-to-earnings ratio of 46.64, a PEG ratio of 4.39 and a beta of 0.89. Danaher Corporation has a 52 week low of $171.00 and a 52 week high of $258.23. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.10 and a current ratio of 1.52.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Monday, October 20th. The conglomerate reported $1.89 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.72 by $0.17. The business had revenue of $6.05 billion for the quarter, compared to analyst estimates of $6 billion. Danaher had a return on equity of 10.92% and a net margin of 14.44%.The firm’s revenue for the quarter was up 4.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.71 earnings per share. On average, analysts predict that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, October 31st. Stockholders of record on Friday, September 26th were paid a $0.32 dividend. This represents a $1.28 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend was Friday, September 26th. Danaher’s dividend payout ratio (DPR) is 26.39%.

Insider Transactions at Danaher

In other Danaher news, SVP Georgeann Couchara sold 5,174 shares of Danaher stock in a transaction on Monday, November 10th. The shares were sold at an average price of $210.42, for a total transaction of $1,088,713.08. Following the completion of the sale, the senior vice president owned 2,625 shares of the company’s stock, valued at approximately $552,352.50. The trade was a 66.34% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Teri List sold 3,298 shares of the company’s stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $226.50, for a total transaction of $746,997.00. Following the sale, the director owned 20,762 shares of the company’s stock, valued at $4,702,593. The trade was a 13.71% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 30,248 shares of company stock worth $6,609,663 in the last quarter. 11.10% of the stock is owned by company insiders.

Analyst Ratings Changes

Several analysts have weighed in on the stock. Cowen reaffirmed a “buy” rating on shares of Danaher in a research note on Wednesday, October 22nd. Evercore ISI increased their price target on Danaher from $226.00 to $245.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 7th. HSBC lifted their price objective on Danaher from $255.00 to $270.00 and gave the company a “buy” rating in a research report on Monday, December 1st. Robert W. Baird set a $247.00 target price on Danaher in a report on Wednesday, October 22nd. Finally, Barclays raised their target price on Danaher from $225.00 to $250.00 and gave the company an “overweight” rating in a research note on Wednesday, October 22nd. Twenty research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $245.75.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.